CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CAR-T 细胞桥接放疗期间的免疫系统暴露
英文原题：Exposure to the immune system during bridging radiotherapy for Car-T cells.
查看英文原题
Exposure to the immune system during bridging radiotherapy for Car-T cells.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
CAR-T 细胞桥接放疗时免疫系统所接受的剂量在患者之间差异很大，而积分剂量是免疫系统所受照射的主要组成部分。
中文摘要
目的
量化桥接放疗实际给予非淋巴瘤免疫细胞的剂量。
材料与方法
识别2023年1月至2024年4月在法国巴黎居里研究所接受嵌合抗原受体（CAR）T细胞输注前后桥接放疗的所有患者，并逐例计算免疫细胞有效剂量。
结果
共纳入9例患者，平均随访6个月；1例患者复发。未报告≥2级毒性。免疫细胞有效剂量中位数为0.56 Gy（范围0.039–2.72 Gy），患者间差异较大。主要剂量贡献来自积分剂量，中位数为0.43 Gy（范围0.039–1.42 Gy）。
结论
CAR-T 桥接放疗期间免疫系统所受剂量因患者而异，积分剂量是免疫系统辐射暴露的主要组成部分。仍需开展前瞻性、可靠研究，评估桥接放疗中放疗技术选择的作用。
展开英文摘要原文
PURPOSE
The objective of this study was to quantify how much dose from bridging radiotherapy is being delivered to non-lymphoma immune cells. MATERIAL AND METHODS: All patients who underwent bridging radiotherapy between January 2023 and April 2024 at the institut Curie (Paris, France) surrounding the infusion of chimeric antigen receptor (Car)-T cells, were identified. The effective dose to the immune cells was calculated for each of them.
RESULTS
Nine patients were included, with a mean follow-up time of 6months; one patient experienced a recurrence. No grade 2+ toxicity was reported. Median effective dose to the immune cells was 0.56Gy (range: 0.039-2.72Gy) and varied between patients. The main contribution came from the integral dose (0.43Gy, range: 0.039-1.42Gy).
CONCLUSIONS
The doses received by the immune system when undergoing bridging radiotherapy for Car-T cells can vary considerably from one patient to another, and the integral dose represents the primary part of this exposure of the immune system. Prospective solid data is needed in this context to evaluate the role of choice of radiotherapy techniques in bridging radiotherapy.
论文信息
- 作者
- Loap P、Decroocq J、Birsen R、Johnson N、Bouscary D、Kirova Y
- 第一作者单位
- Departement of Radiation Oncology, institut Curie, Paris, France; Laboratoire d'imagerie translationnelle en oncologie (Lito), institut Curie, Orsay, France.France
- 通讯作者单位
- Departement of Radiation Oncology, institut Curie, Paris, France. Electronic address: youlia.kirova@curie.fr.France
- 期刊
- Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique2025 Apr
- 原文标识
- PubMed 40253845 · DOI 10.1016/j.canrad.2025.104595